Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)

Launched by INTERNATIONAL VACCINE INSTITUTE · Nov 10, 2023

Keywords

ClinConnect Summary

The GLOBE-HPV trial is an important study looking at how common high-risk types of Human Papillomavirus (HPV) are among girls and women aged 9 to 50 years in various countries, including some in South Asia and sub-Saharan Africa. The study aims to gather information through surveys to understand how many women have HPV and how often it lasts, especially in young women who are sexually active. It will also include smaller studies to explore factors like gender roles and social stigma that may affect women’s access to HPV prevention, screening, and treatment services.

To participate in this study, women need to be between 9 and 50 years old and have lived in the selected community for at least three months. Those who are 18 or older can provide their own consent, while younger participants will need permission from a parent or guardian. If you join the study, you can expect to answer some questions and possibly provide samples for testing. Overall, this trial aims to gather crucial data that can help improve HPV prevention and care for women in the participating regions.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. 9 to 50 years old (for urban and rural CSSs) at the time of enrollment.
• • 2. Resident in the selected community for at least the past 3 months (with the exception of pastoralists, refugees, and commercial sex workers).
• • 3. Able to understand the purpose of the study and study procedures.
• • 4. If aged 18 years or older or legally considered an emancipated minor, able and willing to provide consent to participate in the study including sample collection.
• • 5. If aged \<18 years (and not considered an emancipated minor), supported in their participation by a parent or guardian who is able and willing to provide consent, and
• • 6. If aged \<18 years (and not considered an emancipated minor), able and willing to provide assent to participate in the study.
• Exclusion Criteria:
• • 1. Decline consent to participate any activity of the study.
• • 2. A medical condition or other reason, not directly related to HPV infection or HPV-related diseases, in the opinion of the investigator, precludes enrolment in the study.